These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23194656)

  • 1. Potential use of inflammation and early immunological event biomarkers in assessing vaccine safety.
    Mastelic B; Lewis DJ; Golding H; Gust I; Sheets R; Lambert PH
    Biologicals; 2013 Mar; 41(2):115-24. PubMed ID: 23194656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mode of action of adjuvants: implications for vaccine safety and design.
    Mastelic B; Ahmed S; Egan WM; Del Giudice G; Golding H; Gust I; Neels P; Reed SG; Sheets RL; Siegrist CA; Lambert PH
    Biologicals; 2010 Sep; 38(5):594-601. PubMed ID: 20659806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive markers of safety and immunogenicity of adjuvanted vaccines.
    Mastelic B; Garçon N; Del Giudice G; Golding H; Gruber M; Neels P; Fritzell B
    Biologicals; 2013 Nov; 41(6):458-68. PubMed ID: 24071553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of "Systems Vaccinology" to Evaluate Inflammation and Reactogenicity of Adjuvanted Preventative Vaccines.
    Lewis DJ; Lythgoe MP
    J Immunol Res; 2015; 2015():909406. PubMed ID: 26380327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety biomarkers for development of vaccines and biologics: Report from the safety biomarkers symposium held on November 28-29, 2017, Marcy l'Etoile, France.
    Doubovetzky M; Ataman-Önal Y; Chousterman B; Feroldi E; Garçon N; Grillet MH; Kramer D; Laurent S; Lewis DJM; Luna E; Manigold T; Syntin P; Burdin N; Fraisse L; Jackson N
    Vaccine; 2020 Dec; 38(51):8055-8063. PubMed ID: 33187767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-licensure evaluation of vaccine safety: current status and future directions. Symposium organised by the International Alliance for Biological Standardization (IABS) in Barcelona, Spain, 27-28 April 2011.
    Black S; Egan W; Lambert PH
    Biologicals; 2012 Sep; 40(5):382-3. PubMed ID: 21982850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of vaccine adjuvants: focus on autoimmunity.
    van der Laan JW; Gould S; Tanir JY;
    Vaccine; 2015 Mar; 33(13):1507-14. PubMed ID: 25659277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Principles of Vaccination.
    Zepp F
    Methods Mol Biol; 2016; 1403():57-84. PubMed ID: 27076125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next Generation Vaccine Biomarkers workshop October 30-31, 2014--Ottawa, Canada.
    Twine SM; Fulton KM; Spika J; Ouellette M; Raven JF; Conlan JW; Krishnan L; Barreto L; Richards JC
    Hum Vaccin Immunother; 2015; 11(12):2923-30. PubMed ID: 26383909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine safety evaluation: Practical aspects in assessing benefits and risks.
    Di Pasquale A; Bonanni P; Garçon N; Stanberry LR; El-Hodhod M; Tavares Da Silva F
    Vaccine; 2016 Dec; 34(52):6672-6680. PubMed ID: 27836435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ontology-Based Vaccine Adverse Event Representation and Analysis.
    Xie J; He Y
    Adv Exp Med Biol; 2017; 1028():89-103. PubMed ID: 29058218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies.
    Destexhe E; Prinsen MK; van Schöll I; Kuper CF; Garçon N; Veenstra S; Segal L
    J Pharmacol Toxicol Methods; 2013; 68(3):367-73. PubMed ID: 23624216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to the assessment of vaccine herd protection in clinical trials.
    Clemens J; Shin S; Ali M
    Lancet Infect Dis; 2011 Jun; 11(6):482-7. PubMed ID: 21616458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005.
    Finch R; Hunter PA
    J Antimicrob Chemother; 2006 Sep; 58 Suppl 1():i3-i22. PubMed ID: 17003063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
    André FE; Foulkes MA
    Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A global perspective on vaccine safety.
    Duclos P
    Vaccine; 2004 May; 22(15-16):2059-63. PubMed ID: 15121323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IABS international scientific workshop--Mode of Action of Adjuvants: implications for vaccine safety and design, April 29-30, 2010, Bethesda, MD, USA.
    Seemann S; Dodet B
    Vaccine; 2011 Apr; 29(17):3340. PubMed ID: 21335035
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.